Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

【24h】

Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

机译：阶段1/2 U3-1402的第一人体研究，抗人表皮生长因子受体3（HER3）抗体 - 药物缀合物，在HER3表达先进/不可切除或转移性乳腺癌中，包括三重阴性乳房癌症（TNBC）或HER3低疾病

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
专利

1. Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：阶段1/2 U3-1402的第一人体研究，抗人表皮生长因子受体3（HER3）抗体 - 药物缀合物，在HER3表达先进/不可切除或转移性乳腺癌中，包括三重阴性乳房癌症（TNBC）或HER3低疾病
2. BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTORPOSITIVE (ER plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC) [J] . Bachelot Thomas, Villanueva Cristian, Royce Melanie, The Breast : . 2015,第Suppla3期

机译：Bolero-4：第2阶段，开放标签，多中心，单手臂试验研究一线血酮（前夕）与雌激素受体展（PTS）在绝经后患者（PTS）中的Letrozole（Let）的疗效和安全性（ER Plus ），人表皮生长因子受体2阴性（HER2-）转移性或局部先进的不可切除的乳腺癌（BC）
3. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. [J] . Nielsen DL, Bjerre KD, Jakobsen EH, Journal of Clinical Oncology . 2011,第36期

机译：吉西他滨加多西他赛与多西他赛治疗主要是人类表皮生长因子受体2阴性的局部晚期或转移性乳腺癌的患者：丹麦乳腺癌合作小组进行的一项随机III期研究。
4. Effect of curcumin on NF-κB P105/50 expression on triple-negative breast cancer (TNBC) and its possible mechanism of action [C] . Retno Murwanti, Eva Kholifah, B. S. Ari Sudarmanto, International Conference on Biological Science . 2020

机译：姜黄素对三重阴性乳腺癌（TNBC）对NF-κBP105/ 50表达的影响及其动作机制
5. Combating resistance to epidermal growth factor receptor inhibitors in triple negative breast cancer. [D] . Madden, Julie M. 2014

机译：在三阴性乳腺癌中对抗表皮生长因子受体抑制剂的耐药性。
6. Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [O] . José Baselga, Patricia Gómez, Richard Greil, -1

机译：转移性三阴性乳腺癌患者抗表皮生长因子受体单克隆抗体西妥昔单抗联合顺铂与单独顺铂的随机II期研究
7. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. [O] . Baselga, José, Gómez, Patricia P, Greil, Richard R, 2013

机译：抗表皮生长因子受体单克隆抗体西妥昔单抗联合顺铂与单独顺铂在转移性三阴性乳腺癌患者中的随机II期研究。

Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

著录项

相似文献

相关主题

期刊订阅